ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 Corporate One, 84 Hotham Street, Preston, VIC 3072 Australia Telephone: + 61 3 9863 6472 [email protected] | www.arovella.com ASX Release 6 October 2026 AROVELLA PRESENTS AT THE CELL AND GENE MEETING IN PHOENIX, ARIZONA Highlights:...
Cell and Gene Innovation Spotlight Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
In the deck
Earlier from Arovella Therapeutics
- Notice of Annual General Meeting/Proxy Form
- The path to first patient dosing
- 2026 ESG Report
- Notification of 2026 AGM Date
- Clinical manufacturing batch released, first site activated
Later from Arovella Therapeutics
- Second Clinical Batch Released for Immediate Patient Use
- Arovella receives R&D tax rebate of $4.03 million
- Quarterly Activities/Appendix 4C Cash Flow Report
- First Patient Dosed with ALA-101
- Complete tumour clearance in gastric cancer animal study
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics